CONCORD
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Concord Drugs Temporarily Holds Fundraising And Capital Increase Proposal
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
(([email protected];;))
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
(([email protected];;))
Concord Drugs Puts Fundraising And Capital Increase On Hold
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
(([email protected];))
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
(([email protected];))
Concord Drugs To Consider Fund Raising
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
(([email protected];;))
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
(([email protected];;))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Concord Drugs do?
Concord Drugs Limited, founded in 1995, is a leading pharmaceutical company in India. Specializing in generics, branded, and specialty pharmaceuticals, Concord is known for its diverse product portfolio of over 200 prescription and over-the-counter products.
Who are the competitors of Concord Drugs?
Concord Drugs major competitors are Unick Fix-A-Form, Kabra Drugs, Panjon, Guj. Inject (Kerala), Veerhealth Care, ANG Lifesciences, Vilin Bio Med. Market Cap of Concord Drugs is ₹34 Crs. While the median market cap of its peers are ₹36 Crs.
Is Concord Drugs financially stable compared to its competitors?
Concord Drugs seems to be less financially stable compared to its competitors. Altman Z score of Concord Drugs is 2.77 and is ranked 4 out of its 8 competitors.
Does Concord Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Concord Drugs allocated its funds?
Companies resources are allocated to majorly unproductive assets like Capital Work in Progress, Inventory, Accounts Receivable
How strong is Concord Drugs balance sheet?
Balance sheet of Concord Drugs is moderately strong.
Is the profitablity of Concord Drugs improving?
No, profit is decreasing. The profit of Concord Drugs is ₹0.47 Crs for Mar 2024, ₹0.99 Crs for Mar 2023 and ₹1.59 Crs for Mar 2022
Is the debt of Concord Drugs increasing or decreasing?
The net debt of Concord Drugs is decreasing. Latest net debt of Concord Drugs is ₹16.97 Crs as of Mar-25. This is less than Mar-24 when it was ₹17.31 Crs.
Is Concord Drugs stock expensive?
Yes, Concord Drugs is expensive. Latest PE of Concord Drugs is 102, while 3 year average PE is 22.23. Also latest EV/EBITDA of Concord Drugs is 12.28 while 3yr average is 10.92.
Has the share price of Concord Drugs grown faster than its competition?
Concord Drugs has given lower returns compared to its competitors. Concord Drugs has grown at ~-5.26% over the last 1yrs while peers have grown at a median rate of -1.87%
Is the promoter bullish about Concord Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Concord Drugs is 54.39% and last quarter promoter holding is 54.39%.
Are mutual funds buying/selling Concord Drugs?
There is Insufficient data to gauge this.